Ainos, Inc..
AIMD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Ainos, Inc., formerly Amarillo Biosciences, Inc., is a biotechnology company focused on the development of therapeutics for unmet medical needs, particularly in infectious diseases. Their lead product candidate is Veldona, an interferon-alpha oral formulation, intended for the treatment of various v...Show More
Better Health for All
10
Ainos' core business is dedicated to health improvement, with 100% of its R&D budget focused on developing therapeutics and diagnostics for unmet medical needs, including 13 years of research for its AI Nose technology.
1
Its product portfolio, including the AI Nose and VELDONA therapies, delivers exceptional health benefits, with no evidence of harmful products. The AI Nose technology, with 85-90% accuracy in healthcare applications, aims to detect excretion odors in long-term care settings, potentially preventing skin injuries and reducing caregiver fatigue.
2
This focus on early detection emphasizes preventative health measures. VELDONA low-dose interferon therapy has shown significant improvements in inflammation (10.5% to 44.4% reduction) and reduced steroid dependency in three cats with feline chronic gingivostomatitis.
3
It is also being developed for human conditions like HIV-related oral warts and Sjögren's Syndrome, which currently lack effective treatments.
4
VELDONA has a favorable safety profile, with no significant side effects observed in trials and a history of use in various animal species since 1985.
5
The company conducts randomized, controlled clinical trials for its VELDONA-based drugs, with TFDA approval for the HIV oral warts trial and IRB clearance for the Sjögren's Syndrome trial.
6
The AI Nose aims to reduce caregiver burden and improve working conditions in long-term care facilities, addressing a projected shortfall of over 570,000 caregivers in Japan.
7
The company's operations do not directly involve global health crisis response, price accessibility, risk transparency, health externalities, health equity programs, healthcare data responsibility, mental health initiatives, pharma patent flexibility, nutrition and food safety, healthcare education, or addiction mitigation.
Fair Money & Economic Opportunity
0
Ainos, Inc. is a biotechnology company focused on therapeutics and diagnostics. The 'Fair Money & Economic Opportunity' value assesses companies involved in lending, insuring, moving, or storing money, and how they democratize access to fair financial services. The provided articles detail Ainos, Inc.'s financial performance as a biotech company, its stock trading activities, clinical trials, and product development in the healthcare sector. None of the articles contain any information or data indicating that Ainos, Inc. operates in the financial services industry or offers any products or services related to lending, insurance, or consumer finance. Consequently, there is no evidence to score Ainos, Inc. against any of the KPIs for this value, as they are not applicable to its business model.
Fair Pay & Worker Respect
-50
As of December 20, 2024, Ainos, Inc. reported that 0% of its 44 full-time employees are represented by a labor union or are party to a collective bargaining agreement.
1
No evidence was found regarding living wage coverage, CEO-to-median employee pay ratio, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Ainos, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The company received a Nasdaq deficiency letter on January 5, 2023.
1
No ethics-related regulatory fines were reported in the past three years.
2
Kind to Animals
-30
Ainos, Inc. uses animals for pre-clinical studies to evaluate the safety profile of their medications and plans to begin animal clinical trials for potential veterinary applications of VELDONA®.
1
The company initiated a clinical study using 30 cats for feline chronic gingivostomatitis (FCGS) from May 2024 to March 2025.
2
VELDONA® was initially approved in 1985 for feline leukemia in cats and canine parvovirus in dogs, and has been tested in 28 studies on various animal species including mice, cats, dogs, ferrets, chickens, rats, guinea pigs, horses, calves/cows, and pigs.
3
The company's partner, Tah-An, has manufactured pharmaceuticals for livestock since 1966, but there is no evidence of Ainos' direct involvement in animal agriculture operations or sourcing.
4
No War, No Weapons
0
No specific, concrete evidence regarding Ainos, Inc.'s involvement with arms manufacturing, military contracts, or conflict facilitation was found in the provided articles. The articles explicitly state they do not contain data relevant to AIMD.US or the specific metrics for the 'No War, No Weapons' value.
1
Planet-Friendly Business
0
No specific, quantifiable data points related to Ainos, Inc.'s environmental performance, policies, or targets were found across the provided articles. The articles primarily focus on company information, product technology, and partnerships, without disclosing metrics such as greenhouse gas emissions, renewable energy usage, water consumption, waste diversion rates, or climate-related financial disclosures.
1
While one article mentions a technology achieving high efficiency in nitrogen-oxygen separation using one-third the energy of conventional methods,
2
this refers to a product's capability rather than the company's own operational environmental performance or its adoption of such technology for its own facilities.
Respect for Cultures & Communities
0
The provided articles focus on Ainos, Inc.'s technological advancements, business development, financial performance, and investor relations. No specific, concrete data points or facts were found regarding formal partnerships with community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, community complaint resolution times, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
1
Therefore, no KPIs could be scored based on the evidence provided.
Safe & Smart Tech
-30
Ainos, Inc. reported no material cybersecurity challenges or incidents of unauthorized data use for the fiscal year ending December 31, 2023.
1
The company's privacy policy states that data is encrypted during transfer using HTTPS and other methods, which aligns with industry-standard practices.
2
However, the policy, dated July 11, 2025, references the EU-US Privacy Shield, a framework that was invalidated in 2020, indicating a significant gap in its privacy certifications and regulatory compliance.
3
While the policy states users can revoke consent, access, correct, delete, and transfer data, it lacks specific details on the ease of exercising these rights, suggesting moderate data control options with potential friction.
4
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding Ainos, Inc.'s waste management practices, product recyclability, packaging sustainability, or any other metrics related to the 'Zero Waste & Sustainable Products' ethical value. While one article mentions the potential of the company's AI Nose product to reduce waste in semiconductor manufacturing,
1
this refers to the product's capability when used by a partner, not to Ainos, Inc.'s own implemented waste reduction initiatives or sustainable product design practices.